pubmed-article:9402073 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:9402073 | lifeskim:mentions | umls-concept:C0019693 | lld:lifeskim |
pubmed-article:9402073 | lifeskim:mentions | umls-concept:C0086413 | lld:lifeskim |
pubmed-article:9402073 | lifeskim:mentions | umls-concept:C0679646 | lld:lifeskim |
pubmed-article:9402073 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
pubmed-article:9402073 | lifeskim:mentions | umls-concept:C1317574 | lld:lifeskim |
pubmed-article:9402073 | lifeskim:mentions | umls-concept:C0086931 | lld:lifeskim |
pubmed-article:9402073 | lifeskim:mentions | umls-concept:C1456501 | lld:lifeskim |
pubmed-article:9402073 | pubmed:issue | 4 | lld:pubmed |
pubmed-article:9402073 | pubmed:dateCreated | 1997-12-22 | lld:pubmed |
pubmed-article:9402073 | pubmed:abstractText | We conducted a longitudinal study of participants in phase I and II HIV vaccine safety and immunogenicity trials to examine changes in sexual risk behavior that are associated with risk of HIV transmission. The participants were 48 HIV-negative men and women enrolled in one of two placebo-controlled HIV vaccine trials conducted at San Francisco General Hospital. There was a significant increase in insertive unprotected anal intercourse (UAI) from 9% at baseline (trial entry), to 13% at the month 6 assessment, to 20% at the month 12 assessment (p = .02). The primary predictor of either insertive or receptive UAI during the vaccine trials was having engaged in this behavior prior to entry (p = .001). Higher-risk behavior was also seen among participants who were younger and had multiple sexual partners (each, p = .06) and who indicated that one of their reasons for participation in the vaccine trial was hope of protection from HIV infection (p = .07). These findings indicate that despite instructions otherwise, participants with a history of high-risk behavior or who express hope of protection from HIV infection by enrolling in vaccine trials may be candidates for more intensive risk-behavior counseling prior to and during their participation. | lld:pubmed |
pubmed-article:9402073 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9402073 | pubmed:language | eng | lld:pubmed |
pubmed-article:9402073 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9402073 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:9402073 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9402073 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:9402073 | pubmed:month | Dec | lld:pubmed |
pubmed-article:9402073 | pubmed:issn | 1077-9450 | lld:pubmed |
pubmed-article:9402073 | pubmed:author | pubmed-author:KralV AVA | lld:pubmed |
pubmed-article:9402073 | pubmed:author | pubmed-author:ChesneyM AMA | lld:pubmed |
pubmed-article:9402073 | pubmed:author | pubmed-author:ChambersD BDB | lld:pubmed |
pubmed-article:9402073 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:9402073 | pubmed:day | 1 | lld:pubmed |
pubmed-article:9402073 | pubmed:volume | 16 | lld:pubmed |
pubmed-article:9402073 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:9402073 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:9402073 | pubmed:pagination | 266-71 | lld:pubmed |
pubmed-article:9402073 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
pubmed-article:9402073 | pubmed:meshHeading | pubmed-meshheading:9402073-... | lld:pubmed |
pubmed-article:9402073 | pubmed:meshHeading | pubmed-meshheading:9402073-... | lld:pubmed |
pubmed-article:9402073 | pubmed:meshHeading | pubmed-meshheading:9402073-... | lld:pubmed |
pubmed-article:9402073 | pubmed:meshHeading | pubmed-meshheading:9402073-... | lld:pubmed |
pubmed-article:9402073 | pubmed:meshHeading | pubmed-meshheading:9402073-... | lld:pubmed |
pubmed-article:9402073 | pubmed:meshHeading | pubmed-meshheading:9402073-... | lld:pubmed |
pubmed-article:9402073 | pubmed:meshHeading | pubmed-meshheading:9402073-... | lld:pubmed |
pubmed-article:9402073 | pubmed:meshHeading | pubmed-meshheading:9402073-... | lld:pubmed |
pubmed-article:9402073 | pubmed:meshHeading | pubmed-meshheading:9402073-... | lld:pubmed |
pubmed-article:9402073 | pubmed:meshHeading | pubmed-meshheading:9402073-... | lld:pubmed |
pubmed-article:9402073 | pubmed:meshHeading | pubmed-meshheading:9402073-... | lld:pubmed |
pubmed-article:9402073 | pubmed:meshHeading | pubmed-meshheading:9402073-... | lld:pubmed |
pubmed-article:9402073 | pubmed:meshHeading | pubmed-meshheading:9402073-... | lld:pubmed |
pubmed-article:9402073 | pubmed:meshHeading | pubmed-meshheading:9402073-... | lld:pubmed |
pubmed-article:9402073 | pubmed:meshHeading | pubmed-meshheading:9402073-... | lld:pubmed |
pubmed-article:9402073 | pubmed:meshHeading | pubmed-meshheading:9402073-... | lld:pubmed |
pubmed-article:9402073 | pubmed:meshHeading | pubmed-meshheading:9402073-... | lld:pubmed |
pubmed-article:9402073 | pubmed:meshHeading | pubmed-meshheading:9402073-... | lld:pubmed |
pubmed-article:9402073 | pubmed:year | 1997 | lld:pubmed |
pubmed-article:9402073 | pubmed:articleTitle | Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. | lld:pubmed |
pubmed-article:9402073 | pubmed:affiliation | Center for AIDS Prevention Studies, Department of Medicine, University of California, San Francisco, 94105, USA. margaret_chesney@quickmail.ucsf.edu | lld:pubmed |
pubmed-article:9402073 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:9402073 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9402073 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9402073 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9402073 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9402073 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9402073 | lld:pubmed |